Jun 11, 2021 / 02:30PM GMT
Shehnaaz Suliman - Alector, Inc. - President, COO & Interim Chief Business Officer
Good morning. I am Shehnaaz Suliman, President and COO of Alector. We'd like to welcome everyone to the first of our thought leader series, in which we invite experts in neurodegeneration to share perspectives on their own research and clinical efforts as well as provide a perspective on Alector's research and development programs.
We are hoping to host these events periodically to continue to stay current on developments in the field, especially as it relates to biomarkers and clinical outcomes. The focus of today's discussion is on FTD and AL001, our lead sortilin inhibitor program, which is developed for FTD patients with a progranulin mutation and currently in Phase III.
Before we begin, a reminder that we will be making forward-looking statements that are subject to assumptions, risks and uncertainties.
The agenda for today starts with an overview of immuno-neurology provided by Arnon Rosenthal, our Founder and CEO. Robert Paul, our CMO, will provide an overview of the frontotemporal
Alector Inc to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers